No hantavirus vaccine is licensed in the Americas or Europe, and all current candidates remain in preclinical or early Phase 1 stages as of September 2026. Recent mRNA platforms from UTMB and Moderna-Korea University collaborations demonstrated single-dose protection in animal models against Andes virus, while Korea University advances a two-year national project toward GMP manufacturing. However, these efforts lack Phase 3 trials, established regulatory pathways, or the multi-year safety and efficacy data required for approval. Historical timelines for similar vaccines, strain diversity, and absence of large-scale human testing sustain the market's strong consensus that licensure will not occur this year.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
4% peluang
$136,375 Vol.
$136,375 Vol.
Dec 31, 2026
4% peluang
$136,375 Vol.
$136,375 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is licensed in the Americas or Europe, and all current candidates remain in preclinical or early Phase 1 stages as of September 2026. Recent mRNA platforms from UTMB and Moderna-Korea University collaborations demonstrated single-dose protection in animal models against Andes virus, while Korea University advances a two-year national project toward GMP manufacturing. However, these efforts lack Phase 3 trials, established regulatory pathways, or the multi-year safety and efficacy data required for approval. Historical timelines for similar vaccines, strain diversity, and absence of large-scale human testing sustain the market's strong consensus that licensure will not occur this year.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Pasar Dibuka: May 4, 2026, 10:39 AM ET
Volume
$136,375Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No hantavirus vaccine is licensed in the Americas or Europe, and all current candidates remain in preclinical or early Phase 1 stages as of September 2026. Recent mRNA platforms from UTMB and Moderna-Korea University collaborations demonstrated single-dose protection in animal models against Andes virus, while Korea University advances a two-year national project toward GMP manufacturing. However, these efforts lack Phase 3 trials, established regulatory pathways, or the multi-year safety and efficacy data required for approval. Historical timelines for similar vaccines, strain diversity, and absence of large-scale human testing sustain the market's strong consensus that licensure will not occur this year.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$136,375Tanggal Berakhir
Jan 1, 2027Pasar Dibuka
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No hantavirus vaccine is licensed in the Americas or Europe, and all current candidates remain in preclinical or early Phase 1 stages as of September 2026. Recent mRNA platforms from UTMB and Moderna-Korea University collaborations demonstrated single-dose protection in animal models against Andes virus, while Korea University advances a two-year national project toward GMP manufacturing. However, these efforts lack Phase 3 trials, established regulatory pathways, or the multi-year safety and efficacy data required for approval. Historical timelines for similar vaccines, strain diversity, and absence of large-scale human testing sustain the market's strong consensus that licensure will not occur this year.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan